FISH or not to FISH-Therapeutic Implications of sequential FISH studies in diagnosing B-cell Double-Hit and Triple Hit lymphomas

Abstract

Ayesha A. Pandit and Henry Hongrong Cai

Why FISH... Patients with High Grade B Cell Lymphomas / Double Hit or Triple Hit or HGBL-DH/TH comprise around 10% of new- ly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) and typically demonstrate poor response to standard initial therapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; RCHOP). They are also shown to have limited sur- vival when compared to those without HGBL-DH/TH. There has been a retrospective analysis on 394 patient samples and detected 19 cases of HGBL-DH (12%). After treatment with an- thracycline-containing regimens, the HGBL-DH patients had a significantly shorter median OS of 8.2 months compared with 56.8 months in non- HGBL-DH patients [1, 2].

PDF